SCHEMBL4182610

SCHEMBL4182610

COc1ccccc1CC(=O)c1c(O)c2cccnc2n(-c2cccc(OC(F)(F)F)c2)c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
MAPT P10636 3/20 0.40
CSNK1D P48730 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4D Q08499 1/20 0.40
TOP2A P11388 1/20 0.39
SCN5A Q14524 2/20 0.37
SCN9A Q15858 2/20 0.37
TP53 P04637 2/20 0.37
GAA P10253 2/20 0.37
THRB P10828 1/20 0.37
KCNH2 Q12809 1/20 0.37
F2RL3 Q96RI0 1/20 0.37
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
POLB P06746 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4191918 0.94 PDE4B (0.41) ADORA2AADORA1MAPTPDE4BPDE4D
SCHEMBL4197150 0.90 PDE4B (0.41) MAPTPDE4BPDE4DTOP2ASCN5A
SCHEMBL4188055 0.89 MAPT (0.49) MAPTCSNK1DPDE4BPDE4DTP53
SCHEMBL4194572 0.88 PDE4B (0.41) MAPTPDE4BPDE4DTOP2ASCN5A
SCHEMBL4194573 0.88 MAPT (0.41) MAPTPDE4BPDE4DTOP2ATP53
SCHEMBL2409603 0.87 FEN1 (0.43) MAPTPDE4BPDE4DPOLBTDP1
SCHEMBL4187682 0.86 PDE4B (0.43) MAPTPDE4BPDE4DTOP2ASCN5A
SCHEMBL4192220 0.86 PDE4B (0.39) MAPTPDE4BPDE4DTOP2ASCN5A
SCHEMBL4190805 0.86 TP53 (0.43) MAPTPDE4BPDE4DTP53GAA
SCHEMBL4185730 0.85 PDE4B (0.43) PDE4BPDE4DTOP2ASCN5ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1925617-B1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA PHARM CO LTD (JP) 2012-11-14 EP disclosed
US-8193356-B2 Heterocycle compound, and production process and application thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-05 US disclosed
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-05-21 US disclosed
EP-1925617-A1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA Pharmaceutical Co., Ltd. (JP) 2008-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof PDE3B, PDE4B, PDE7A ADORA2A 2222/4885ADORA1 3152/4885MAPT 4865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.